Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced its participation in the 2021 Virtual Wells Fargo Biotech Corporate Access Day, scheduled for April 6, 2021. The event will feature one-on-one and small group meetings with key management including Dr. William (Wei) Cao, Dr. Martina Sersch, and Dr. Kevin Xie. Gracell focuses on developing affordable cell therapies using its advanced FasTCAR and TruUCAR technology platforms, aiming to address challenges in conventional CAR-T therapies. For more details, attendees are advised to contact their Wells Fargo representative.

SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will participate in the upcoming 2021 Virtual Wells Fargo Biotech Corporate Access Day. Details of the event are as follows:

2021 Virtual Wells Fargo Biotech Corporate Access Day

One-on-one and small group meetings: April 6, 2021

Management participants: Dr. William (Wei) Cao, Founder and CEO; Dr. Martina Sersch, M.D., CMO; Dr. Kevin Xie, CFO

For more information, please contact your Wells Fargo representative.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Media Contact
Marvin Tang
Marvin.tang@gracellbio.com

Investor Contact
Gracie Tong
Gracie.tong@gracellbio.com

FAQ

When is Gracell's participation in the 2021 Virtual Wells Fargo Biotech Corporate Access Day?

Gracell will participate in the event on April 6, 2021.

Who will represent Gracell at the Virtual Wells Fargo Biotech Corporate Access Day?

Management participants include Dr. William (Wei) Cao, Dr. Martina Sersch, and Dr. Kevin Xie.

What is the focus of Gracell Biotechnologies?

Gracell focuses on discovering and developing highly efficacious and affordable cell therapies.

What technologies does Gracell use for its therapies?

Gracell utilizes the FasTCAR and TruUCAR technology platforms.

What challenges in CAR-T therapies is Gracell addressing?

Gracell aims to overcome issues like lengthy manufacturing times, suboptimal production quality, and high therapy costs.